Cancer Risk Higher for Men vs Women at Most Shared Anatomic Sites
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11 percent
Melanoma And Other Skin Cancers
Primary Care-Based Screening Ups Thin Melanoma Detection
Incidence of melanoma thicker than 4 mm did not differ significantly for screened and unscreened patients
Update Shows Relatlimab + Nivolumab Slows Advanced Melanoma
Progression-free survival prolonged with relatlimab + nivolumab versus nivolumab alone for previously untreated advanced melanoma
Opdualag Approved for Unresectable, Metastatic Melanoma
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.
Relatlimab-Nivolumab Ups PFS in Untreated Advanced Melanoma
Combination provides greater benefit than nivolumab alone for progression-free survival in untreated metastatic or unresectable melanoma
Keytruda Approved for Adjuvant Treatment IIB, IIC Melanoma Following Resection
Approval was based on data from the phase 3 KEYNOTE-716 trial, which enrolled 976 participants.
Giving Nivolumab/Ipilimumab First Ups Overall Survival in Melanoma
Two-year overall survival 72 percent for those starting with N/I, 52 percent for those starting with dabrafenib/trametinib
Relatlimab-Nivolumab Fixed-Dose Combo Gets Priority Review for Melanoma
The application is supported by data from the phase 2/3 RELATIVITY-047 trial.
Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Nemvaleukin Alfa Fast Tracked for Mucosal Melanoma
Nemvaleukin alfa is an investigational, engineered fusion protein consisting of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
